What is the difference between isolate, broad-spectrum, and full-spectrum CBD?

Isolate is pure CBD with no THC; broad-spectrum includes multiple cannabinoids without THC; full-spectrum includes the full plant profile with up to 0.3% THC.

Is your CBD THC-free?

Our isolate and broad-spectrum products are THC-free. Product pages and labels list exact cannabinoid content.

How do I take CBD oil?

Most people place the oil under the tongue for 60-90 seconds before swallowing; start low and adjust gradually.

Hemp-derived CBD is federally legal under the 2018 Farm Bill; check your local regulations.

How do I place an order?

Choose a product above and tap Order, or email info@biomedrxcbd.com and we'll confirm your order by email.

BiomedRx CBD | Full & Broad-Spectrum Wellness Products

Educational

Hemp Testing Lab Standards Update for May 2026: New Potency Calibration and Terpene Profiling

Accurate cannabinoid testing is the backbone of hemp compliance. Under the 2018 Farm Bill, "hemp" is legally defined by a delta-9 THC concentration of not more than 0.3 percent on a dry-weight basis, and USDA rules require that regulatory sampling be analyzed by DEA-registered laboratories using methods that account for the conversion of THCA into delta-9 THC — so-called total THC. When calibration standards or reporting conventions shift, the practical result is that a batch reported as compliant under one method can read differently under another, which is why producers watch protocol changes closely.

High-performance liquid chromatography (HPLC) remains the dominant analytical technique for potency because, unlike gas chromatography, it does not heat the sample and therefore reports the acidic and neutral cannabinoids separately. Re-calibrating potency curves and tightening reference standards can change reported values at the margins, and terpene profiling — while not a compliance requirement in itself — is increasingly used by labs to characterize product identity and by producers to document consistency across harvests.

For operators, the prudent posture is to confirm which validated method a lab uses, retain the Certificate of Analysis for every batch, and re-test any inventory whose original results sit close to the 0.3 percent line. Because federal and state testing requirements continue to evolve, treat any single lab report as a snapshot tied to a specific method and sampling date rather than a permanent guarantee.

Sources: Agriculture Improvement Act of 2018 (Congress.gov); FDA — Cannabis and CBD Regulation

May 3, 202613 min read

Informative

CBD Product Label Compliance Checklist for May 2026: Federal and State Requirements You Cannot Miss

Labeling is where hemp-derived CBD compliance most often succeeds or fails. The FDA has repeatedly warned companies that market CBD with claims to diagnose, cure, mitigate, treat, or prevent disease, because such claims cause a product to be treated as an unapproved drug under the Federal Food, Drug, and Cosmetic Act. The agency has also stated it is unlawful under current law to add CBD to foods or to market it as a dietary supplement. For a consumer product, that means claim language must stay away from disease and structure/function overreach, and it should carry the standard disclosure that statements have not been evaluated by the FDA.

Beyond claims, a defensible label carries an accurate potency declaration tied to a batch-specific Certificate of Analysis, a clear ingredient list, net quantity, a lot or batch identifier, and manufacturer or distributor contact information. Many states layer additional requirements on top of the federal floor — QR-code links to lab results, specific warning statements, or registration of the product with a state agriculture or health department — so a label that is compliant in one state may need adjustment in another.

A practical audit walks each SKU through three lenses: does the marketing avoid prohibited claims, does the potency on the label match a current COA, and does the label meet the specific state's disclosure rules where the product is sold. Because the regulatory picture continues to shift as Congress works through Farm Bill reauthorization, treat any checklist as a living document rather than a one-time exercise.

Sources: FDA — Cannabis and CBD Regulation; Agriculture Improvement Act of 2018 (Congress.gov)

May 10, 20269 min read

Field Notes

Choosing Your First CBD Product: A Beginner's Guide to Product Format, Dosage, and Expectations

If you are new to CBD, the format you choose mostly affects how quickly and how consistently it enters your system. Sublingual tinctures, held under the tongue, are absorbed partly through the oral mucosa and tend to act faster than swallowed products; capsules and gummies pass through digestion, so onset is slower and, because of first-pass metabolism in the liver, the amount that reaches the bloodstream can vary from person to person. Topicals are applied to a specific area of skin and are generally used for localized comfort rather than whole-body effects.

Dosage varies because body weight, individual metabolism, product concentration, and formulation all influence how a given amount is experienced, and there is no single FDA-established dose for over-the-counter CBD. The National Center for Complementary and Integrative Health notes that while cannabidiol has been studied for several conditions, the evidence base for most consumer uses is still limited, and CBD can interact with certain medications — which is why it is sensible to start low, go slow, and talk with a healthcare provider, especially if you take prescription drugs.

A reasonable approach for a first two weeks is to pick one format, keep the dose and timing consistent, and jot down simple notes on what you notice. Track the batch's Certificate of Analysis so you know the actual cannabinoid content, and remember that these are wellness products, not treatments for any medical condition — statements here have not been evaluated by the FDA.

Sources: NIH NCCIH — Cannabidiol (CBD); FDA — Cannabis and CBD Regulation

May 18, 20267 min read